Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesMyeloproliferative Diseases and Disorders, Poorly Differentiated NeoplasmsDRG 828-myeloproliferative-disorders-or-poorly-differentiated-neoplasms-with-major-o-r-procedures-without-cc-mcc
    Ask Trek AI about this page

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    DRG 828 encompasses admissions for myeloproliferative disorders or poorly differentiated neoplasms involving major operating room procedures without a Complication or Comorbidity or Major Complication or Comorbidity, focusing on cases driven by surgical resource use. This Diagnosis-Related Group matters for inpatient reimbursement because grouping determines the prospective payment amount and aligns payment with expected resource intensity for operative oncology and hematology care.

    Customize your policy alerts

    Sign up for drg 828 policy alerts

    Get alerted when payer policies referencing 828 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 828 Overview

    DRG 828 covers hospital admissions for patients with myeloproliferative disorders or poorly differentiated neoplasms who undergo major operating room procedures and do not have a Complication or Comorbidity or a Major Complication or Comorbidity. This Diagnosis-Related Group groups cases by clinical complexity tied to surgical intervention rather than medical comorbidity, which affects relative resource use and payment. It matters for Medicare payment because assignment to this Diagnosis-Related Group determines the base prospective payment and influences hospital revenue for operative oncology and hematology admissions. Accurate coding of diagnoses and procedures is essential to ensure correct Diagnosis-Related Group assignment and reimbursement.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Trials assessing perioperative and intraoperative management strategies for patients with myeloproliferative disorders or poorly differentiated neoplasms undergoing major operative procedures: these studies evaluate protocols such as blood product management, thrombosis prophylaxis, and timing of cytoreductive therapy around surgery in a predominantly inpatient surgical population. The focus population includes adults with active myeloproliferative neoplasms or poorly differentiated hematologic malignancies who require major OR procedures, and the research question is how to minimize surgical complications (bleeding, thrombosis, infection) and length of stay. Results inform hospital clinicians and payers about best-practice perioperative pathways that can reduce resource utilization and readmissions for this high-risk DRG group.
    • Comparative effectiveness studies of different inpatient procedural approaches and supportive care bundles for cytoreductive or marrow-directed major procedures: these studies compare outcomes of alternative operative techniques, anesthesia strategies, or bundled supportive measures (e.g., standardized transfusion thresholds, antimicrobial prophylaxis, and ICU admission criteria) in patients with myeloproliferative disorders or poorly differentiated neoplasms without major complication codes. The population includes surgical inpatients whose primary diagnosis falls into this DRG and the objective is to identify which approaches yield better short-term clinical outcomes, lower complication rates, and more efficient use of inpatient resources. Findings help providers choose cost-effective care pathways and help payers predict expected resource needs and appropriate reimbursement for similar episodes.
    • Post-discharge and outcomes research on readmission risk, functional recovery, and long-term hematologic control after major OR procedures: these observational cohort studies track patients discharged after major surgery to determine drivers of 30- and 90-day readmissions, impacts of perioperative oncology management on disease progression, and functional status recovery in survivors of myeloproliferative disorders or poorly differentiated neoplasms. The patient group comprises those assigned to this DRG who survive hospitalization and require ongoing hematology-oncology follow-up; the research identifies modifiable factors (transition-of-care processes, outpatient hematology access, rehabilitation needs) that influence downstream utilization. Such evidence is valuable for hospitals and payers aiming to reduce readmissions, allocate post-acute services appropriately, and tie inpatient episode payments to longer-term outcomes.

    Related Codes

    820-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Lymphoma and Leukemia with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    821-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Lymphoma and Leukemia with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    822-LYMPHOMA-AND-LEUKEMIA-WITH-MAJOR-O-R-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC: Inpatient Reimbursement Overview

    823-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures with MCC: Inpatient Reimbursement Overview

    824-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITH-CC

    Lymphoma and Non-Acute Leukemia with Other Procedures with CC: Inpatient Reimbursement Overview

    825-LYMPHOMA-AND-NON-ACUTE-LEUKEMIA-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    826-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with MCC: Inpatient Reimbursement Overview

    827-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-MAJOR-O-R-PROCEDURES-WITH-CC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Major O.R. Procedures with CC: Inpatient Reimbursement Overview

    829-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITH-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms: Inpatient Reimbursement Overview

    830-MYELOPROLIFERATIVE-DISORDERS-OR-POORLY-DIFFERENTIATED-NEOPLASMS-WITH-OTHER-PROCEDURES-WITHOUT-CC-MCC

    Myeloproliferative Disorders or Poorly Differentiated Neoplasms with Other Procedures without CC/MCC: Inpatient Reimbursement Overview

    Showing 1–10 of 27

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.